Revisiting Secondary Information Related to Pharmacogenetic Testing
Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guide...
Gespeichert in:
Veröffentlicht in: | Frontiers in genetics 2021-10, Vol.12, p.741395 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 741395 |
container_title | Frontiers in genetics |
container_volume | 12 |
creator | Haga, Susanne B |
description | Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guidelines that have been developed for whole exome or genome sequencing applications for management of secondary findings (though slightly different from PGx testing in that these refer to detection of variants in multiple genes, some with clinical significance and actionability), no corresponding guidelines have been developed for PGx clinical laboratories. Nonetheless, patient and provider education will remain key components of any PGx testing program to minimize adverse responses related to secondary findings. |
doi_str_mv | 10.3389/fgene.2021.741395 |
format | Article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_proquest_miscellaneous_2583313227</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d00d45bd823341dfac93cc3bbdbbf516</doaj_id><sourcerecordid>2583313227</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-97f297fbc856aad53c4cfaa5786c0f02879398d0a7c31638e78a8b77ca7c65933</originalsourceid><addsrcrecordid>eNpVUctKBDEQDKKorH6AF5mjl12T6ckkcxFk8bEgKD7OoSePNTI70WRW8O_NuCoaCGkqXdWVFCFHjM4AZHPqlra3s5KWbCYqBg3fIvusrqupzND2n3qPHKb0QvOqGgCodskeVDVvoGb7ZH5v333yg--XxYPVoTcYP4pF70Jc4eBDX9zbDgdriiEUd8-YUR3GyYPXxaNNI_GA7Djskj38Pifk6fLicX49vbm9WszPb6Y6jxumjXBl3q2WvEY0HHSlHSIXstbU0VKKBhppKAoNrAZphUTZCqEzMNqFCVlsdE3AF_Ua_Sp7VQG9-gJCXCqM2VdnlaHUVLw1sswPZsahbkBraFvTto5n9Qk522i9rtuVNdr2Q8Tun-j_m94_q2V4V5IzwYBngZNvgRje1vkj1MonbbsOexvWSZVcAjAoS5Fb2aZVx5BStO53DKNqzFJ9ZanGLNUmy8w5_uvvl_GTHHwCzQiclA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2583313227</pqid></control><display><type>article</type><title>Revisiting Secondary Information Related to Pharmacogenetic Testing</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Haga, Susanne B</creator><creatorcontrib>Haga, Susanne B</creatorcontrib><description>Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guidelines that have been developed for whole exome or genome sequencing applications for management of secondary findings (though slightly different from PGx testing in that these refer to detection of variants in multiple genes, some with clinical significance and actionability), no corresponding guidelines have been developed for PGx clinical laboratories. Nonetheless, patient and provider education will remain key components of any PGx testing program to minimize adverse responses related to secondary findings.</description><identifier>ISSN: 1664-8021</identifier><identifier>EISSN: 1664-8021</identifier><identifier>DOI: 10.3389/fgene.2021.741395</identifier><identifier>PMID: 34659361</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>clinical reporting ; education ; Genetics ; incidental (secondary) findings ; patient consent</subject><ispartof>Frontiers in genetics, 2021-10, Vol.12, p.741395</ispartof><rights>Copyright © 2021 Haga.</rights><rights>Copyright © 2021 Haga. 2021 Haga</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-97f297fbc856aad53c4cfaa5786c0f02879398d0a7c31638e78a8b77ca7c65933</citedby><cites>FETCH-LOGICAL-c465t-97f297fbc856aad53c4cfaa5786c0f02879398d0a7c31638e78a8b77ca7c65933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517135/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517135/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34659361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haga, Susanne B</creatorcontrib><title>Revisiting Secondary Information Related to Pharmacogenetic Testing</title><title>Frontiers in genetics</title><addtitle>Front Genet</addtitle><description>Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guidelines that have been developed for whole exome or genome sequencing applications for management of secondary findings (though slightly different from PGx testing in that these refer to detection of variants in multiple genes, some with clinical significance and actionability), no corresponding guidelines have been developed for PGx clinical laboratories. Nonetheless, patient and provider education will remain key components of any PGx testing program to minimize adverse responses related to secondary findings.</description><subject>clinical reporting</subject><subject>education</subject><subject>Genetics</subject><subject>incidental (secondary) findings</subject><subject>patient consent</subject><issn>1664-8021</issn><issn>1664-8021</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVUctKBDEQDKKorH6AF5mjl12T6ckkcxFk8bEgKD7OoSePNTI70WRW8O_NuCoaCGkqXdWVFCFHjM4AZHPqlra3s5KWbCYqBg3fIvusrqupzND2n3qPHKb0QvOqGgCodskeVDVvoGb7ZH5v333yg--XxYPVoTcYP4pF70Jc4eBDX9zbDgdriiEUd8-YUR3GyYPXxaNNI_GA7Djskj38Pifk6fLicX49vbm9WszPb6Y6jxumjXBl3q2WvEY0HHSlHSIXstbU0VKKBhppKAoNrAZphUTZCqEzMNqFCVlsdE3AF_Ua_Sp7VQG9-gJCXCqM2VdnlaHUVLw1sswPZsahbkBraFvTto5n9Qk522i9rtuVNdr2Q8Tun-j_m94_q2V4V5IzwYBngZNvgRje1vkj1MonbbsOexvWSZVcAjAoS5Fb2aZVx5BStO53DKNqzFJ9ZanGLNUmy8w5_uvvl_GTHHwCzQiclA</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Haga, Susanne B</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20211001</creationdate><title>Revisiting Secondary Information Related to Pharmacogenetic Testing</title><author>Haga, Susanne B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-97f297fbc856aad53c4cfaa5786c0f02879398d0a7c31638e78a8b77ca7c65933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>clinical reporting</topic><topic>education</topic><topic>Genetics</topic><topic>incidental (secondary) findings</topic><topic>patient consent</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haga, Susanne B</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haga, Susanne B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Revisiting Secondary Information Related to Pharmacogenetic Testing</atitle><jtitle>Frontiers in genetics</jtitle><addtitle>Front Genet</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>12</volume><spage>741395</spage><pages>741395-</pages><issn>1664-8021</issn><eissn>1664-8021</eissn><abstract>Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guidelines that have been developed for whole exome or genome sequencing applications for management of secondary findings (though slightly different from PGx testing in that these refer to detection of variants in multiple genes, some with clinical significance and actionability), no corresponding guidelines have been developed for PGx clinical laboratories. Nonetheless, patient and provider education will remain key components of any PGx testing program to minimize adverse responses related to secondary findings.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>34659361</pmid><doi>10.3389/fgene.2021.741395</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1664-8021 |
ispartof | Frontiers in genetics, 2021-10, Vol.12, p.741395 |
issn | 1664-8021 1664-8021 |
language | eng |
recordid | cdi_proquest_miscellaneous_2583313227 |
source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | clinical reporting education Genetics incidental (secondary) findings patient consent |
title | Revisiting Secondary Information Related to Pharmacogenetic Testing |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A13%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Revisiting%20Secondary%20Information%20Related%20to%20Pharmacogenetic%20Testing&rft.jtitle=Frontiers%20in%20genetics&rft.au=Haga,%20Susanne%20B&rft.date=2021-10-01&rft.volume=12&rft.spage=741395&rft.pages=741395-&rft.issn=1664-8021&rft.eissn=1664-8021&rft_id=info:doi/10.3389/fgene.2021.741395&rft_dat=%3Cproquest_doaj_%3E2583313227%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2583313227&rft_id=info:pmid/34659361&rft_doaj_id=oai_doaj_org_article_d00d45bd823341dfac93cc3bbdbbf516&rfr_iscdi=true |